LVTX - Lava Tx Accounting Value per Share

Official company branding of Lava Tx (LVTX)

LAVA Therapeutics N.V. (LVTX) is shielded from macroeconomic shocks due to stable demand for biotechnology. The estimated book value per share illustrates net asset dynamics, where the value of 0.48 represents the most recent figure. The business foundation is the GAMA platform, which creates high barriers to entry for competitors. Growth prospects are based on the market launch of innovative bispecific antibodies for cancer treatment.

LVTX LAVA Therapeutics N.V. Net Asset Value per Share (07/04/2022 - 12/06/2025)

LVTX (LAVA Therapeutics NV): analytical breakdowns and indicator data

- share price and expert price forecast:
Stock Quotes Lava Tx|LVTX - Analyst Forecast Prices
- market capitalization statistics:
Market Valuation LAVA Therapeutics N.V.|LVTX - Business Value
- balance sheet net asset value indicators:
Net Assets per Single Share LAVA Therapeutics|LVTX - Total Stockholders' Equity|Market Value to Book Value Ratio lavatherapeutics.com|LVTX - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Capital LAVA Therapeutics N.V.|LVTX - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Lava Tx|LVTX - Company Cumulative Debt|Debt to Book Capitalization Ratio LAVA Therapeutics N.V.|LVTX - Company Long-Term Debt|Company Short-Term Debt LAVA Therapeutics|Quick Ratio lavatherapeutics.com
- earnings and multiples data:
LVTX - Annual Net Income
Basic company analysis:LVTX - lavatherapeutics.com
Manufactured products of Lava Tx

Book value per share determines the portion of equity per security, reflecting the actual value of the company's net assets. For LAVA Therapeutics N.V. (LVTX), analyzing the book value per share allows for an assessment of the company's financial stability against the backdrop of costly gamma-delta T-cell developments and risks associated with the clinical trial results of bispecific antibodies.

Competitor analysis for LAVA Therapeutics N.V.

IBRX: Accounting Value per Share|Immunocore Corp - Book Price of a Share|JANX (Janux Therapeutics) - Accounting Value per Share|Equity per Share RCUS|Net Assets per Single Share Zymeworks|Net Asset Value per Share Tango Therapeutics Inc TNGX|Net Assets per Single Share Iovance (IOVA)|Immatics Biotechnologies - Equity per Share|Book Value per Share XNCR (Xencor, Inc.)|CMPX - Accounting Value per Share|REPL - Net Assets per Single Share|Net Asset Value per Share Lyell|Innate Pharma, S.A. (IPHA) - Net Assets per Single Share|PYXS (Pyxis Oncology) - Net Assets per Single Share|Net Assets per Single Share Compugen Ltd|Net Asset Value per Share iobiotech.com IOBT|Book Value per Share STRO|MiNK Therapeutics Inc. (INKT) - Book Value of One Share|Werewolf Therapeutics, Inc. - Accounting Value per Share|Immix Biopharma Inc. (IMMX) - Net Asset Value per Share|ALXO: Accounting Value per Share|Accounting Value of a Share CUE (cuebiopharma.com)|PDSB: Book Value per Share|SONN - Net Assets per Share|Net Assets per Single Share MAIA Biotechnology Inc|Accounting Value per Share Liminatus (LIMN)|Net Assets per Single Share NextCure, Inc. (NXTC)|Accounting Value per Share leaptx.com LPTX|Intensity Therapeutics, Inc. - Accounting Value per Share|Book Value per Share Sensei Biotherapeutics Inc SNSE|TOVX - Net Assets per Single Share|GRTS (Gritstone bio, Inc.) - Equity per Share|Kineta, Inc. (KA) - Net Assets per Single Share|Net Asset Value per Share neximmune.com (NEXI)|Accounting Value per Share TSBX|VCNX - Book Value of One Share|Accounting Value per Share HARP (Harpoon Tx)